Advanced Care: HSCT and Lymphoma Treatment
At a Glance
A stem cell transplant (HSCT) may replace the abnormal immune system in STK4 deficiency and potentially reduce lifelong immune support, but it has substantial risks. If lymphoma develops, treatment must be individualized with close infection monitoring by immunology and oncology specialists.
While daily management with medications and infusions is the primary approach for STK4 deficiency, some families and medical teams may consider advanced treatments. These options—specifically hematopoietic stem cell transplantation (HSCT) and specialized care for lymphoma—are complex and require a high level of coordination between specialists in immunology, oncology, and transplant medicine [1][2].
Hematopoietic Stem Cell Transplantation (HSCT)
An HSCT, often called a bone marrow transplant, is currently the only treatment that has the potential to cure the hematopoietic defects of STK4 deficiency. The goal of the transplant is to replace the patient’s immune system (which has the STK4 mutation) with a healthy immune system from a donor [2].
The Potential Benefits
A successful transplant can lead to complete donor chimerism, which means all the new white blood cells in the body come from the healthy donor [2]. In cases that have been reported, a successful transplant can normalize T-cell and B-cell counts, potentially eliminating the need for daily preventative medications and lifelong immunoglobulin infusions [2].
The Risks and Challenges
Because STK4 deficiency is so rare, there is no universal “playbook” for transplantation, and the risks are significant:
- Mortality Risk: Researchers and transplant specialists have cautioned that historical mortality (death) rates for STK4 deficiency after HSCT have been high [1][2]. Because there are so few cases, it is difficult to give an exact percentage, and current risks depend heavily on the patient’s age, organ health, and the transplant center’s specific experience [1].
- Conditioning: Before the transplant, a patient must undergo conditioning, which uses chemotherapy to clear out their old immune system to make room for the new one [2]. This process is physically demanding and temporarily leaves the patient with profound immunosuppression. Conditioning regimens are highly center- and patient-specific.
- Graft-versus-Host Disease (GVHD): This occurs when the new donor cells see the patient’s body as “foreign” and attack it. Doctors use medications like sirolimus or methotrexate to help prevent this [2].
Due to these risks, some experts suggest that more data is needed before HSCT can be recommended for every patient. The decision often depends on the severity of the infections or if complications like lymphoma develop [1]. Early transplant evaluation should be presented as an individualized specialist discussion.
Managing Lymphoma Complications
As discussed in previous sections, children and adults with STK4 deficiency may develop lymphoma (a cancer of the immune system) [1]. If this happens, the patient will work closely with an oncologist (a cancer specialist).
Treatment Approaches
Treatment is tailored to the specific type of lymphoma. One common form seen in this condition is Diffuse Large B-cell Lymphoma (DLBCL) [3][4].
- Chemotherapy: The specific chemotherapy regimen depends on biopsy findings, age, stage, and organ function. Pediatric patients are usually treated according to pediatric mature-B-cell lymphoma protocols. While regimens such as R-CHOP have been used successfully in some STK4 patients to achieve remission (particularly in adults), this should not be viewed as the default standard for every child [3].
- Supportive Care: Because the patient already has a weakened immune system, oncology teams take extra precautions. This often includes individualized supportive measures like continuing IVIG (immunoglobulin) during chemotherapy and using medications like G-CSF (growth factors) to help the body make white blood cells more quickly after a treatment cycle [3].
- Targeted Therapies: If the lymphoma is linked to the Epstein-Barr virus (EBV) or involves CD20-positive B cells, the team may also use rituximab, a medication that specifically targets and eliminates those B cells [2][5].
The Importance of Specialized Care
Because chemotherapy further suppresses the immune system, patients with STK4 deficiency require extremely close monitoring for infections during cancer treatment. It is common for these patients to be cared for at major academic medical centers where immunologists and oncologists can work together daily to balance cancer-fighting treatments with immune protection [3].
The outlook for lymphoma in STK4 deficiency is still being studied. While some patients have achieved remission with standard treatments, others have experienced more than one type of lymphoma over time, making long-term follow-up essential [3][6].
Common questions in this guide
Can a stem cell transplant cure STK4 deficiency?
What are the main risks of HSCT for STK4 deficiency?
How is lymphoma treated in someone with STK4 deficiency?
Why is specialized care important during lymphoma treatment?
What is graft-versus-host disease after a stem cell transplant?
Get notified when new evidence is published on Combined immunodeficiency due to STK4 deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (6)
- 1
Diversity in Serine/Threonine Protein Kinase-4 Deficiency and Review of the Literature.
Cagdas D, Halacli SO, Tan C, et al.
The journal of allergy and clinical immunology. In practice 2021; (9(10)):3752-3766.e4 doi:10.1016/j.jaip.2021.05.032.
PMID: 34146746 - 2
Hematopoietic stem cell transplantation in serine/threonine kinase 4 (STK4) deficiency: Report of two cases and literature review.
Uygun V, Keleş S, Daloğlu H, et al.
Pediatric transplantation 2023; (27(2)):e14439 doi:10.1111/petr.14439.
PMID: 36394186 - 3
A case report of sinusoidal diffuse large B-cell lymphoma in a STK4 deficient patient.
Ashrafi F, Klein C, Poorpooneh M, et al.
Medicine 2020; (99(9)):e18601 doi:10.1097/MD.0000000000018601.
PMID: 32118703 - 4
Epidermodysplasia Verruciformis and Vδ2 γδ T-cell Expansion in STK4 Deficiency.
Ying W, Long X, Vandergriff T, et al.
Journal of clinical immunology 2024; (44(8)):172 doi:10.1007/s10875-024-01780-z.
PMID: 39110273 - 5
STK4 deficiency and EBV-associated lymphoproliferative disorders, emphasis on histomorphology, and review of literature.
Saglam A, Cagdas D, Aydin B, et al.
Virchows Archiv : an international journal of pathology 2022; (480(2)):393-401 doi:10.1007/s00428-021-03147-w.
PMID: 34604912 - 6
EBV Negative Lymphoma and Autoimmune Lymphoproliferative Syndrome Like Phenotype Extend the Clinical Spectrum of Primary Immunodeficiency Caused by STK4 Deficiency.
Schipp C, Schlütermann D, Hönscheid A, et al.
Frontiers in immunology 2018; (9()):2400 doi:10.3389/fimmu.2018.02400.
PMID: 30386345
This page is for informational purposes only and does not constitute medical advice. Decisions about HSCT or lymphoma treatment in STK4 deficiency should be made with an experienced immunology, oncology, and transplant team.